E-Z-EM: To Market AngioStent to EC

PRESS RELEASE

For More Information Please Contact:

Michael P. Cody
Director of Corporate Communications
AngioDynamics, Inc.
Phone: (518) 798-1215 ext. 140
Fax:   (518) 798-3625
E-mail: mcody@angiodynamics.com


                   ANGIODYNAMICS TO MARKET NEW STENT

        Queensbury, NY, August 12, 1998 -- AngioDynamics, Inc. a wholly
owned subsidiary of E-Z-EM, Inc. (AMEX: EZM.A and EZM.B) announced as of
July 24, 1998 it has been granted permission to affix the CE marking on its
AngioStent peripheral stent.

        This clearance will allow AngioDynamics to immediately market the
AngioStent into the European Community.

        Eamonn Hobbs, AngioDynamics President and CEO said: "The ability to
affix the CE marking on our AngioStent will allow us to pursue manufacturing
and marketing the AngioStent for peripheral vascular applications.  The
AngioStent will be manufactured in our Enniscorthy, Ireland facility, which
is ISO9001 and EN46001 certified.  The stent will be mounted on our
proprietary balloon delivery system;  therefore, the manufacturing process
will be entirely vertically integrated.  The AngioStent is already listed in
Australia and sales will continue there as well.

        This product approval positions AngioDynamics as a stand-alone
manufacturer and marketer and we intend to lever our franchise with
interventional radiologists to be a significant player in the global
peripheral stent market."

        William Appling, AngioDynamics Vice President, Product Development
said: "We believe the AngioStent for peripheral vascular applications has
significant advantages over competitive stents.  The platinum alloy used is
recognized as being one of the most biocompatible materials available. The
extremely low thrombogenicity of the Platinum alloy makes the AngioStent a
good choice for low blood flow areas in the peripheral vascular system. The
high radiopacity is a distinct advantage in positioning the stent in the
exactly the right location and then to clearly identify that location
post-placement.  The most unique feature of the AngioStent is the ability to
remove it through a sheath if the placement is less than optimal. Other
stents must be removed by higher risk, open surgical methods.  Because the
AngioStent is manufactured from a single strand of platinum alloy wire, it
may be removed by snaring it and pulling it into a small percutaneously
placed sheath.  This removal process is no more invasive than the placement
of the stent itself.

        Mr. Appling added:  "Developing the AngioStent for coronary use has
expedited the design process for peripheral applications.  Our stent has the
advantage of being very flexible which is an important consideration if
tortuous vasculature has to be crossed to reach the stenosis. Our internal
research indicates that over 150,000 patients are treated with stents each
year in the United States for stenotic lesions of the renal and iliac
arteries."

        The statements made in this press release contain certain
forward-looking statements that involve a number of risks and uncertainties.
Actual events or results may differ from the company's expectations.  In
addition to matters described in this release, future actions by the FDA,
results of pending or future clinical trials, as well as the risk factors
listed from time to time in the SEC filings of E-Z-EM, Inc. including but
not limited to its Form 10-Q for the quarter ended May 31, 1998, as well as
its Annual Report on Form 10-K, may affect the actual results achieved by
the Company.


End